Advertisement
Screener

Xencor, Inc (XNCR) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

Xencor, Inc Share-based Payment Arrangement, Expense

Xencor, Inc (XNCR) reported Share-based Payment Arrangement, Expense of $53.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-02-27

  • Xencor, Inc share-based payment arrangement, expense for the quarter ending 2020-12-31 was $8.54M, a 18.15% increase year-over-year.
  • Xencor, Inc share-based payment arrangement, expense for the quarter ending 2020-09-30 was $8.32M, a 12.57% decline year-over-year.
  • Xencor, Inc share-based payment arrangement, expense for the quarter ending 2020-06-30 was $8.23M, a 11.52% decline year-over-year.
  • Xencor, Inc share-based payment arrangement, expense for the quarter ending 2020-03-31 was $6.51M, a 11.20% increase year-over-year.
  • Xencor, Inc share-based payment arrangement, expense for fiscal 2024 was $53.30M, a 0.93% decline from fiscal 2023.
  • Xencor, Inc share-based payment arrangement, expense for fiscal 2023 was $53.80M, a 10.02% increase from fiscal 2022.
  • Xencor, Inc share-based payment arrangement, expense for fiscal 2022 was $48.90M, a 32.16% increase from fiscal 2021.
  • Xencor, Inc share-based payment arrangement, expense for fiscal 2021 was $37.00M, a 17.09% increase from fiscal 2020.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 monthShare-based Payment Arrangement, Expense 12 month as first filed
2024-12-31$53.30M
10-K · filed 2025-02-27
2023-12-31$53.80M
10-K · filed 2025-02-27
2022-12-31$48.90M
10-K · filed 2025-02-27
2021-12-31$37.00M
10-K/A · filed 2025-02-24
2020-12-31$8.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$16.86M
derived: sum of 2 quarters · filed 2023-02-27
$25.09M
derived: sum of 3 quarters · filed 2023-02-27
$31.60M
10-K · filed 2023-02-27
$31.62M
10-K · filed 2021-02-24
2020-09-30$8.32M
10-Q · filed 2020-11-06
$16.55M
derived: sum of 2 quarters · filed 2020-11-06
$23.06M
10-Q · filed 2020-11-06
$30.29M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$8.23M
10-Q · filed 2020-08-05
$14.74M
10-Q · filed 2020-08-05
$21.97M
derived: sum of 3 quarters · filed 2022-02-24
$31.48M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$6.51M
10-Q · filed 2020-05-08
$13.74M
derived: sum of 2 quarters · filed 2022-02-24
$23.25M
derived: sum of 3 quarters · filed 2022-02-24
$32.56M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$7.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$16.74M
derived: sum of 2 quarters · filed 2022-02-24
$26.04M
derived: sum of 3 quarters · filed 2022-02-24
$31.90M
10-K · filed 2022-02-24
$31.85M
10-K · filed 2020-02-25
2019-09-30$9.51M
10-Q · filed 2020-11-06
$18.82M
derived: sum of 2 quarters · filed 2020-11-06
$24.67M
10-Q · filed 2020-11-06
$29.75M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$9.30M
10-Q · filed 2020-08-05
$15.16M
10-Q · filed 2020-08-05
$20.23M
derived: sum of 3 quarters · filed 2021-02-24
$26.35M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$5.86M
10-Q · filed 2020-05-08
$10.93M
derived: sum of 2 quarters · filed 2021-02-24
$17.05M
derived: sum of 3 quarters · filed 2021-02-24
$21.93M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$5.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$11.20M
derived: sum of 2 quarters · filed 2021-02-24
$16.08M
derived: sum of 3 quarters · filed 2021-02-24
$20.55M
10-K · filed 2021-02-24
2018-09-30$6.12M
10-Q · filed 2019-11-05
$11.00M
derived: sum of 2 quarters · filed 2019-11-05
$15.47M
10-Q · filed 2019-11-05
$18.91M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$4.88M
10-Q · filed 2019-08-07
$9.35M
10-Q · filed 2019-08-07
$12.79M
derived: sum of 3 quarters · filed 2020-02-25
$16.40M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$4.47M
10-Q · filed 2019-05-09
$7.91M
derived: sum of 2 quarters · filed 2020-02-25
$11.52M
derived: sum of 3 quarters · filed 2020-02-25
$14.96M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$3.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$7.04M
derived: sum of 2 quarters · filed 2020-02-25
$10.49M
derived: sum of 3 quarters · filed 2020-02-25
$13.65M
10-K · filed 2020-02-25
2017-09-30$3.60M
10-Q · filed 2018-11-05
$7.05M
derived: sum of 2 quarters · filed 2018-11-05
$10.21M
10-Q · filed 2018-11-05
$12.20M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30$3.45M
10-Q · filed 2018-08-07
$6.61M
10-Q · filed 2018-08-07
$8.60M
derived: sum of 3 quarters · filed 2019-02-26
$10.46M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31$3.16M
10-Q · filed 2018-05-07
$5.15M
derived: sum of 2 quarters · filed 2019-02-26
$7.01M
derived: sum of 3 quarters · filed 2019-02-26
$9.05M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$1.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$3.86M
derived: sum of 2 quarters · filed 2019-02-26
$5.89M
derived: sum of 3 quarters · filed 2019-02-26
$7.85M
10-K · filed 2019-02-26
2016-09-30$1.87M
10-Q · filed 2017-11-08
$3.90M
derived: sum of 2 quarters · filed 2017-11-08
$5.86M
10-Q · filed 2017-11-08
$7.34M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$2.03M
10-Q · filed 2017-08-07
$3.99M
10-Q · filed 2017-08-07
$5.48M
derived: sum of 3 quarters · filed 2018-02-28
$6.56M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$1.96M
10-Q · filed 2017-05-10
$3.44M
derived: sum of 2 quarters · filed 2018-02-28
$4.53M
derived: sum of 3 quarters · filed 2018-02-28
$5.72M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$1.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$2.57M
derived: sum of 2 quarters · filed 2018-02-28
$3.76M
derived: sum of 3 quarters · filed 2018-02-28
$4.87M
10-K · filed 2018-02-28
2015-09-30$1.09M
10-Q · filed 2016-11-02
$2.28M
derived: sum of 2 quarters · filed 2016-11-02
$3.39M
10-Q · filed 2016-11-02
$4.14M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$1.19M
10-Q · filed 2016-08-03
$2.30M
10-Q · filed 2016-08-03
$3.05M
derived: sum of 3 quarters · filed 2017-03-01
$3.54M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$1.11M
10-Q · filed 2016-05-02
$1.86M
derived: sum of 2 quarters · filed 2017-03-01
$2.35M
derived: sum of 3 quarters · filed 2017-03-01
$2.71M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$751.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$1.24M
derived: sum of 2 quarters · filed 2017-03-01
$1.60M
derived: sum of 3 quarters · filed 2017-03-01
$1.86M
10-K · filed 2017-03-01
2014-09-30$491.00K
10-Q · filed 2015-11-04
$852.00K
derived: sum of 2 quarters · filed 2015-11-04
$1.11M
10-Q · filed 2015-11-04
$1.27M
derived: sum of 4 quarters · filed 2016-03-08
2014-06-30$361.00K
10-Q · filed 2015-08-05
$639.00K
10-Q · filed 2015-08-05
$783.00K
derived: sum of 3 quarters · filed 2016-03-08
$827.00K
derived: sum of 4 quarters · filed 2016-03-08
2014-03-31$278.00K
10-Q · filed 2015-05-05
$422.00K
derived: sum of 2 quarters · filed 2016-03-08
$466.00K
derived: sum of 3 quarters · filed 2016-03-08
$471.00K
derived: sum of 4 quarters · filed 2016-03-08
2013-12-31$144.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08
$188.00K
derived: sum of 2 quarters · filed 2016-03-08
$193.00K
derived: sum of 3 quarters · filed 2016-03-08
$198.00K
10-K · filed 2016-03-08
2013-09-30$44.00K
10-Q · filed 2014-11-10
$49.00K
derived: sum of 2 quarters · filed 2014-11-10
$54.00K
10-Q · filed 2014-11-10
2013-06-30$5.00K
10-Q · filed 2014-08-01
$10.00K
10-Q · filed 2014-08-01
2013-03-31$5.00K
10-Q · filed 2014-05-15
2012-12-31$29.00K
10-K · filed 2015-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Septerna, Inc. (SEPN)United States$1.783B-63.01
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82